On Wednesday, Shares of Allscripts Healthcare Solutions Inc (NASDAQ:MDRX), lost -0.71% to $15.42.
Allscripts Healthcare Solutions declared recently that its Board of Directors approved a share repurchase program under which Allscripts may purchase up to $150 million of its common stock through December 31, 2018.
Repurchases will be made from cash on hand in addition to a portion of the free cash flow predictable to be generated from the business over the next three years. The share repurchase program is intended, in part, to offset the dilution created by previous administration equity grants.
Allscripts plans to repurchase shares from time to time in the open market or in privately negotiated transactions, subject to market conditions. There is no guarantee as to the exact number of shares or value that will be repurchased under the stock repurchase program, and Allscripts may discontinue purchases at any time. Whether Allscripts makes any repurchases will depend on many factors, counting but not limited to its business and financial performance, the business and market conditions at the time, counting the price of Allscripts shares, and other factors that administration considers relevant.
Allscripts Healthcare Solutions, Inc. provides clinical, financial, electronic health records (EHR), connectivity, hosting, outsourcing, analytics, patient engagement, and population health products and services in the United States and Canada.
Shares of Acorn International, Inc. (ADR) (NYSE:ATV), declined -41.77% to $11.18, during its last trading session.
Acorn International, declared that, due to recent volatility in trading of the Company’s ADSs, the Company will provide a business update for investors on a conference call to be held Tuesday, December 1, 2015 at 8:30 a.m. ET.
Acorn International, Inc., an integrated multi-platform marketing company, develops, promotes, and sells a portfolio of proprietary-branded products; and third parties products in the People’s Republic of China.
Finally, Shares of Allergan PLC (NYSE:AGN), ended its last trade with -1.65% loss, and closed at $317.18.
Allergan plc, declared that it has reached a contract with the New York State Attorney General’s Office to end the litigation under Section 2 of the Sherman Act, and other statutes with the Attorney General over the decision of Forest Laboratories, Inc., declared in February 2014, to cease marketing and selling the now generic version of memantine immediate release tablets. Under the terms of settlement, Allergan admits no liability, has released its counterclaims against New York, and has agreed to make a payment of about $172,000 to the State of New York to assist defray a portion of the state’s litigation expenses. In addition, Allergan withdraws its petition for a writ of certiorari, filed in the Supreme Court of the United States, challenging the decision of the U.S. Court of Appeals for the Second Circuit in New York v. Actavis plc, No. 14-4624 (May 22, 2015).
Allergan plc develops, manufactures, and distributes generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products. It operates in three segments: North American Brands, North American Generics and International, and Anda Distribution.